Drilldown: Medicines
Appearance
Medicines > onset
:
LDL lowering at 2 weeks, max by 4 weeks
or
Prostate volume reduction over 6-12 months 
:
LDL lowering at 2 weeks, max by 4 weeks
or
Prostate volume reduction over 6-12 months 
Use the filters below to narrow your results.
[[:Category:5-alpha-reductase_inhibitors|5α-reductase inhibitor (dual type I/II)]] (1) ·
[[:Category:Androgen_modulators|Androgen modulator]] (1) ·
[[:Category:BPH_treatments|Benign prostatic hyperplasia treatment]] (1) ·
[[:Category:Lipid-lowering_agents|Lipid-lowering agent]] (3) ·
[[:Category:Statins|Statin]] (3)
~2 hours (parent and active β-hydroxy acid metabolite); pharmacodynamic effect lasts 24 hours via target turnover'"`UNIQ--ref-0000017A-QINU`"' (1) ·
~2-3 hours (parent); pharmacodynamic effect 24 hours via target turnover'"`UNIQ--ref-000003D5-QINU`"' (1) ·
~2-4 hours (parent and active β-hydroxy acid metabolite); pharmacodynamic effect 24 hours via target turnover'"`UNIQ--ref-00000807-QINU`"' (1) ·
~5 weeks (much longer than finasteride's ~6 hours)'"`UNIQ--ref-00000D59-QINU`"' (1)
<5% (extensive hepatic first-pass; food enhances absorption of IR, hence the evening-meal dosing)'"`UNIQ--ref-00000808-QINU`"' (1) ·
<5% (extensive hepatic first-pass; statin pharmacology is hepatocellular, not systemic)'"`UNIQ--ref-0000017B-QINU`"' (1) ·
~17% (oral; food slightly reduces absorption)'"`UNIQ--ref-000003D6-QINU`"' (1) ·
~60% (oral)'"`UNIQ--ref-00000D5A-QINU`"' (1)
'''Pregnant individuals should not handle dutasteride capsules''' (skin absorption risk through intact capsule); can cause hypospadias in male fetus.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Previously Category X; FDA removed the blanket statin contraindication in pregnancy in 2021.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (3)
Showing below up to 4 results in range #1 to #4.

